Technology ID
TAB-2695

Human Rotavirus Strains and Vaccines for Neonatal Childhood Protection

E-Numbers
E-150-2013-0
Lead Inventor
Jiang, Baoming (CDC)
Co-Inventors
Glass, Roger (CDC)
Wang, Yuhuan (CDC)
Gentsch, Jon (CDC)
Applications
Vaccines­­­
Therapeutics
Research Materials
Consumer Products
Therapeutic Areas
Infectious Disease
Development Stages
Pre-Clinical (in vitro)
Development Status
  • In vitro data available
  • In vivo data available (animal)
Research Products
Research Equipment
Lead IC
CDC
ICs
CDC
This invention relates to rotavirus vaccine compositions and methods of vaccination. Rotaviral infection is the most commonly occurring gastrointestinal illness of children world, affecting both developed and developing economies. Additionally, rotavirus infections can affect livestock (especially calves and piglets), and resulting mortality/morbidity cause major economic losses for farmers and nations each year.

The vaccine strains include Rotavirus A CDC-9 (P[4]Gl) and CDC-66 (P[4]G2 serotype). These strains represent common rotavirus serotypes and may serve as improvements or alternatives to current live, oral rotavirus vaccine strains. Further, this technology has demonstrated efficacy in a large animal (piglets) modeling.
Commercial Applications
  • Novel rotavirus vaccines
  • Neonatal/childhood vaccination initiatives
  • Rotavirus surveillance programs, important for both developing and developed nations
Competitive Advantages
  • Isolated strains are representative of those involved in community-acquired infection
  • Suitable for the development of improved, broadly effective rotavirus vaccines
  • Can be developed for injection and/or oral vaccine administration
  • Derived vaccines may be administered alone or in combination with other vaccines

Request More Info

Licensing Contact:
Motley, Jonathan
jonathan.motley@nih.gov

Related Inventions

  • E-122-2013-0
  • E-153-2013-0           TAB-3239
    A Novel Thermal Method to Inactivate Rotavirus for Use in Vaccines
  • E-191-2013-2           TAB-2720
    Controlled Expression and Assembly of Human Group-C Rotavirus-like Particles for Creation of Rotavirus Diagnostic Assays and Improved Vaccine Formulations
  • E-521-2013-0

Patents

  • US
    Provisional (PRV) 61/177,393
    Filed on 2009-05-12
  • Patent Cooperation Treaty
    (PCT) PCT/US2010/034537
    Filed on 2010-05-12
  • US Patent 8,822,192
    Filed on 2011-11-11
  • US Patent 9,974,851
    Filed on 2016-07-01
  • US Patent 9,498,526
    Filed on 2014-08-18
  • US Patent 10,500,269
    Filed on 2018-04-18
  • US Patent 11,065,327
    Filed on 2019-11-01
  • US Patent 11,786,589
    Filed on 2021-06-16

Publications

Collaborations

  • Licensing
Date Published